Crescent Biopharma, Inc.
Crescent Biopharma, Inc. (CBIO)
Overview
Crescent Biopharma, Inc. is a Nasdaq-listed, clinical-stage oncology biotechnology company headquartered in Waltham, Massachusetts. The company came into being through a reverse merger completed in June 2025 with GlycoMimetics, Inc. (whose Delaware corporate shell and Nasdaq listing Crescent assumed), paired with a $200 million private placement financing. A second, $185 million private placement closed in December 2025 alongside a strategic partnership with Sichuan Kelun-Biotech. Crescent ended 2025 with approximately $213.2 million in cash, which management says funds operations into 2028 and supports multiple anticipated clinical data readouts beginning in the first quarter of 2027. As a pre-revenue clinical-stage biotech, the company currently generates no product revenue and, like essentially all companies in this category, is accumulating losses as it advances its pipeline through clinical development.
What They Do & How They Make Money
Crescent's stated mission is to "build a world leading oncology company bringing the next wave of therapies for cancer patients," focused on combination therapies and novel modalities targeting solid tumors. Its lead program, CR-001, is a tetravalent bispecific antibody blocking both PD-1 and VEGF — a mechanism the company describes as combining "two complementary, validated mechanisms in oncology" — currently in the Phase 1/2 ASCEND trial, which began dosing patients in February 2026, with proof-of-concept safety and efficacy data expected in the first quarter of 2027. CR-002 is a topoisomerase-inhibitor antibody-drug conjugate (ADC) targeting PD-L1, with an IND submission expected in mid-2026 and Phase 1/2 initiation targeted for the second half of 2026. CR-003 is another topoisomerase-inhibitor ADC, targeting integrin beta-6, already approved in China through Crescent's partner Kelun-Biotech, with Greater China trials expected to begin in the first quarter of 2026. In December 2025, Crescent and Kelun-Biotech struck a partnership under which Kelun-Biotech receives exclusive Greater China rights to CR-001 while Crescent receives exclusive U.S. and European rights to CR-003, with the two companies jointly exploring combination approaches — a structure that lets Crescent access an already-approved China asset while monetizing its lead candidate's China rights. As a clinical-stage company, Crescent has no current product sales; its "business model" is advancing pipeline assets toward regulatory approval and, ultimately, either commercialization or further licensing/partnership deals.
Competitors
Crescent operates in one of oncology's most crowded and closely watched categories — PD-1/PD-L1-based combination therapies and antibody-drug conjugates — competing against:
- Large, well-funded biotech competitors in the PD-1 x VEGF bispecific space, most notably Summit Therapeutics (in partnership with Akeso), whose ivonescimab has generated significant investor and clinical attention in the same mechanistic class as CR-001.
- Large pharmaceutical incumbents such as Merck (Keytruda) and Bristol Myers Squibb (Opdivo), whose established PD-1 franchises set the efficacy and commercial bar that any new bispecific must beat.
- Numerous other clinical-stage biotechs developing topoisomerase-inhibitor ADCs and other novel oncology combination approaches, a highly active area of biopharma R&D investment.
Competitive Position
Crescent's principal assets are its cash runway (into 2028, unusually long for a clinical-stage biotech) and its Kelun-Biotech partnership, which both validates CR-003 (already approved in China) and gives Crescent access to a de-risked asset for U.S./European development while monetizing CR-001's China rights. Its pipeline targets genuinely important, clinically validated oncology mechanisms (PD-1/VEGF bispecifics, ADCs), which increases the odds of eventual clinical and commercial relevance if trials succeed. However, Crescent has no approved products, no revenue, and no manufacturing or commercial infrastructure advantage — its entire value proposition rests on clinical trial outcomes that remain years away, in a mechanistic category (PD-1 x VEGF bispecifics) where Summit Therapeutics/Akeso's ivonescimab is already generating substantial competitive and investor attention. Biotech patents and clinical data provide some intangible-asset protection once (and if) a candidate reaches approval, but pre-clinical-proof-of-concept biotechs like Crescent carry binary risk: a failed ASCEND readout in Q1 2027 would eliminate much of the current competitive thesis. Crescent's path forward depends entirely on CR-001's ASCEND trial data, successful IND clearance and trial initiation for CR-002, and continued execution of the Kelun-Biotech partnership.